In this article

BMY

Follow your favorite stocks CREATE FREE ACCOUNT

Investors are noticing ripe opportunity in Cytokinetics , a late-stage biopharma company targeting medicines for specialty heart diseases, that has seen shares skyrocket in recent months.

Shares of Cytokinetics have jumped about 69% over the past three months and are up 31% year to date. The stock is one of the top-performing San Francisco-based companies profiled by CNBC's Brian Sullivan on Power Lunch this week from the City by the Bay.

The stock surged in early September after the company posted strong phase 3 trial results for its lead cardio drug called Aficamten, a cardiac myosin inhibitor, which showed an improvement in exercise capacity in patients with obstructive hypertrophic cardiomyopathy. Cy

See Full Page